|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM204404843 |
| 003 |
DE-627 |
| 005 |
20231223231950.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.11.008
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0681.xml
|
| 035 |
|
|
|a (DE-627)NLM204404843
|
| 035 |
|
|
|a (NLM)21163707
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xinxin, Ci
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Florfenicol inhibits allergic airway inflammation in mice by p38 MAPK-mediated phosphorylation of GATA 3
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.03.2011
|
| 500 |
|
|
|a Date Revised 20.11.2014
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Florfenicol has been shown to possess anti-inflammatory activity. However, its possible use for asthma has not yet been studied. First we investigated the anti-inflammatory properties of florfenicol using mice asthma model. BALB/c mice were immunized and challenged by ovalbumin. Treatment with florfenicol caused a marked reduction in inflammatory cells and three Th2 type cytokines in the bronchoalveolar lavage fluids of mice. The levels of ovalbumin-specific IgE and airway hyperresponsiveness were significantly altered after treatment with florfenicol. Histological studies using H&E and AB-PAS staining demonstrate that florfenicol substantially inhibited ovalbumin-induced inflammatory cells infiltration in lung tissue and goblet cell hyperplasia in the airway. These results were similar to those obtained with dexamethasone treatment. We then investigated which signal transduction mechanisms could be implicated in florfenicol activity. Our results suggested that the protective effect of florfenicol was mediated by the inhibition of the p38 MAPK-mediated phosphorylation of GATA 3
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Anti-Bacterial Agents
|2 NLM
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents, Non-Steroidal
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a GATA3 Transcription Factor
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin E
|2 NLM
|
| 650 |
|
7 |
|a 37341-29-0
|2 NLM
|
| 650 |
|
7 |
|a Dexamethasone
|2 NLM
|
| 650 |
|
7 |
|a 7S5I7G3JQL
|2 NLM
|
| 650 |
|
7 |
|a florfenicol
|2 NLM
|
| 650 |
|
7 |
|a 9J97307Y1H
|2 NLM
|
| 650 |
|
7 |
|a p38 Mitogen-Activated Protein Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.24
|2 NLM
|
| 650 |
|
7 |
|a Thiamphenicol
|2 NLM
|
| 650 |
|
7 |
|a FLQ7571NPM
|2 NLM
|
| 700 |
1 |
|
|a Chi, Chen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiao, Chu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xue, Xu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yongjun, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Junqing, Cui
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xuming, Deng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 138(2011), 2 vom: 01. Feb., Seite 231-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:138
|g year:2011
|g number:2
|g day:01
|g month:02
|g pages:231-8
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.11.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 138
|j 2011
|e 2
|b 01
|c 02
|h 231-8
|